Pharmaceutical companies are turning more frequently to external manufacturing partners for their development and production needs. A cornerstone of modern drug development strategy, contract development and manufacturing organizations (CDMOs) now produce about 28% of the world’s prescription and non-prescription drugs.¹
Not surprisingly, contract pharma’s share is set to increase, as owner’s and sponsors turn to the operational excellence of CDMO partners to unleash the potential of their intellectual property (IP).
What are the key considerations in technology transfer and scale-up?
Finding the best commercial partner for your program starts with obtaining mission-critical technical capabilities. However, the best place to begin a serious conversation about the firm’s true potential to provide that value should start with a dialogue about the technology transfer process including transferring methods and procedures.